ArticleFrontiers in medicine2026
Diagnostic performance of controlled attenuation parameter for grading hepatic steatosis in MASLD: an MRI-PDFF-referenced study in a Chinese cohort.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to evaluate the diagnostic accuracy of the controlled attenuation parameter (CAP) for grading hepatic steatosis in metabolic dysfunction-associated steatotic liver disease (MASLD), using magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) as the non-invasive reference standard. Methods: This single-center retrospective study included 120 participants (17 healthy controls and 103 patients with MASLD) who underwent MRI-PDFF, transient elastography (TE), and laboratory testing within predefined time intervals. Participants were stratified by MRI-PDFF values into no (S0, Results: CAP values increased progressively with steatosis severity (S3 > S2 > S1 > S0; all Conclusion: CAP showed good diagnostic performance for grading hepatic steatosis in MASLD and may serve as a practical non-invasive tool for steatosis assessment, particularly in resource-limited settings where MRI-PDFF is not readily available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.